[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 3036 Introduced in Senate (IS)]
111th CONGRESS
2d Session
S. 3036
To establish the Office of the National Alzheimer's Project.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
February 24, 2010
Mr. Bayh (for himself, Ms. Collins, and Mr. LeMieux) introduced the
following bill; which was read twice and referred to the Committee on
Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To establish the Office of the National Alzheimer's Project.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``National Alzheimer's Project Act''.
SEC. 2. OFFICE OF THE NATIONAL ALZHEIMER'S PROJECT.
(a) Establishment of Office.--There is established in the Office of
the Secretary of Health and Human Services the Office of the National
Alzheimer's Project (referred to in this Act as the ``Office'').
(b) Purpose of the Office.--The Office shall--
(1) accelerate the development of treatments that would
prevent, halt, or reverse the course of Alzheimer's;
(2) be responsible for the creation and maintenance of an
integrated national plan to overcome Alzheimer's;
(3) help to coordinate the health care and treatment of
citizens with Alzheimer's;
(4) ensure the inclusion of ethnic and racial populations
at higher risk for Alzheimer's or least likely to receive care,
in clinical, research, and service efforts with the purpose of
decreasing health disparities in Alzheimer's;
(5) coordinate with international bodies to integrate and
inform the fight against Alzheimer's globally; and
(6) provide information and coordination of Alzheimer's
research and services across all Federal agencies.
(c) Director of the Office.--
(1) Appointment.--The President shall appoint a Director of
the Office.
(2) Duties of the director.--
(A) In general.--The Director of the Office shall--
(i) oversee the creation and updating of
the national plan described in subparagraph
(B);
(ii) use discretionary authority to
evaluate all Federal programs around
Alzheimer's, including budget requests and
approvals; and
(iii) prepare and submit to the President
the annual budget estimate for the Office.
(B) National plan.--The Director of the Office
shall carry out an annual assessment of the Nation's
progress in preparing for the escalating burden of
Alzheimer's, including both implementation steps and
recommendations for priority actions based on the
assessment.
(3) Service by director.--The Director of the Office shall
serve on the advisory board of the Office of Science and
Technology to promote research efforts into mechanisms to slow
and stop the development of Alzheimer's for those at risk of
developing the disease.
(d) Advisory Council.--
(1) In general.--There is established in the Office an
Advisory Council on Alzheimer's Research and Treatment
(referred to in this Act as the ``Advisory Council'').
(2) Membership.--
(A) Federal members.--The Advisory Council shall be
comprised of the following experts:
(i) A designee of the Centers for Disease
Control and Prevention.
(ii) A designee of the Administration on
Aging.
(iii) A designee of the Centers for
Medicare & Medicaid Services.
(iv) A designee of the Indian Health
Service.
(v) A designee of the Office of the
Director of the National Institutes of Health.
(vi) The Surgeon General.
(vii) A designee of the National Science
Foundation.
(viii) A designee of the Department of
Veterans Affairs.
(B) Non-federal members.--In addition to the
members outlined in subparagraph (A), the Advisory
Council shall include 12 expert members from outside
the Federal Government, which shall include--
(i) 2 Alzheimer patient advocates;
(ii) 2 Alzheimer caregivers;
(iii) 2 health care providers;
(iv) 2 representatives of State health
departments;
(v) 2 researchers with Alzheimer-related
expertise in basic, translational, clinical, or
drug development science; and
(vi) 2 voluntary health association
representatives, including a national
Alzheimer's disease organization that funds
research and has demonstrated experience in
care and patient services, and a State-based
advocacy organization that provides services to
families and professionals, including
information and referral, support groups, care
consultation, education, and safety services.
(3) Meetings.--The Advisory Council shall meet quarterly
and such meetings shall be open to the public.
(4) Advice.--The Advisory Council shall advise the Director
of the Office.
(5) Annual report.--The Advisory Council shall provide to
the Director of the Office--
(A) recommendations for information to be included
in the annual report to Congress by the Office; and
(B) an annually updated national plan.
(e) Annual Report.--The Director of the Office shall submit to
Congress--
(1) an annual report that includes an evaluation of all
nationally and federally funded efforts in Alzheimer's
research, clinical care, institutional, and home- and
community-based programs and their outcomes; and
(2) an annually updated national plan.
(f) Sunset.--The Office shall expire on December 31, 2025.
<all>